| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30aae935fd61f35c5b4292a939e19c5c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
1999-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8932e633d7d62cf28a29841113b4a00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3eeb39790a16521aae6903d8a316cc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d1c834fd4c57f14c33006ec25c9be79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc3e6c74ce4ead0dd8db81f4e7488c2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e3fea937f7baaab2a86e9d26716e216 |
| publicationDate |
2001-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2001010971-A |
| titleOfInvention |
Eye ointment for treatment of eye infections |
| abstract |
PROBLEM TO BE SOLVED: To provide an eye ointment for treating an eye infection, particularly for an eye infection caused by methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE). Providing effective eye ointments. SOLUTION: This ophthalmic ointment for treating ocular infections contains 0.01 to 5.0% of vancomycin hydrochloride as an active ingredient. There is no problem to induce side effects such as toxicity It can maintain a therapeutically effective concentration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7392660-B2 |
| priorityDate |
1999-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |